The text has been copied to the clipboard
Back
Thrombo-embolic prevention after transcatheter aortic valve implantation.
Journal article

Thrombo-embolic prevention after transcatheter aortic valve implantation.

  • Vranckx P Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Stadsomvaart 11, 3500 Hasselt, Belgium and Faculty of Medicine and Life Sciences Hasselt University.
  • Windecker S Swiss Cardiovascular Center Bern, Bern University Hospital, Freiburgstrasse 8, CH-3010 Bern, Switzerland.
  • Welsh RC Mazankowski Alberta Heart Institute, University of Alberta, 11220?83 Ave NW, Edmonton, AB T6G 2B7, Canada.
  • Valgimigli M Swiss Cardiovascular Center Bern, Bern University Hospital, Freiburgstrasse 8, CH-3010 Bern, Switzerland.
  • Mehran R Mazankowski Alberta Heart Institute, University of Alberta, 11220?83 Ave NW, Edmonton, AB T6G 2B7, Canada.
  • Dangas G Mazankowski Alberta Heart Institute, University of Alberta, 11220?83 Ave NW, Edmonton, AB T6G 2B7, Canada.
Show more…
  • 2017-10-12
Published in:
  • European heart journal. - 2017
Anticoagulation
Aortic valve
TAVI
Administration, Oral
Anticoagulants
Aortic Valve Stenosis
Bioprosthesis
Fibrinolytic Agents
Graft Occlusion, Vascular
Heart Valve Prosthesis
Humans
Myocardial Infarction
Postoperative Care
Postoperative Complications
Postoperative Hemorrhage
Practice Guidelines as Topic
Stroke
Thromboembolism
Transcatheter Aortic Valve Replacement
Trauma, Nervous System
Vascular Closure Devices
Venous Thromboembolism
English Transcatheter aortic valve implantation (TAVI) has emerged as a valuable treatment alternative to surgical aortic valve replacement among patients with symptomatic aortic stenosis at increased surgical risk. The rapid technological evolution from early to current-generation TAVI systems with low-profile delivery catheters, bioprosthetic valves with proven midterm durability, and improved positioning and retrieval features have made important contributions to the widespread clinical use of this minimal invasive therapy. Although peri-procedural and long-term thrombotic and bleeding events after TAVI remain a relevant concern, the optimal antithrombotic strategy and duration to mitigate these risks remain unclear. This review provides an overview of recent insights in this field, and highlights current and future antithrombotic trials focusing on optimizing outcomes in patients undergoing TAVI.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/278615
Export to…
JSON data
Dublin Core
BibTeX
RIS (Zotero, …)
Statistics
Document views: 98 File downloads: